The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Prostate Cancer Nuclear Medicine Diagnostics Market During The Forecast Period 2026–2030?
The prostate cancer nuclear medicine diagnostics market has witnessed rapid growth in its size over recent years. It is anticipated to increase from $0.99 billion in 2025 to $1.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. Historically, this expansion can be attributed to several factors, including the development of nuclear medicine infrastructure, a greater reliance on radiotracers in oncology, the widespread presence of gamma camera and PET imaging systems, increasing rates of prostate cancer diagnosis, and the rise in hospital-based imaging services.
The prostate cancer nuclear medicine diagnostics market size is set for significant expansion in the coming years. It is projected to increase to $1.84 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This growth throughout the forecast period stems from developments in radiopharmaceutical creation, the escalating need for accurate cancer staging tools, the broadening scope of personalized oncology diagnostics, increasing capital expenditure in hybrid imaging platforms, and the rising uptake of molecular imaging techniques. Prominent trends for the forecast period include the increasing incorporation of PET and SPECT imaging modalities, the growing utilization of radiopharmaceutical-based diagnostics, heightened demand for functional cancer imaging, the proliferation of hybrid imaging technologies, and an amplified focus on precise disease staging.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15906&type=smp
What Underlying Factors Are Accelerating The Growth Of The Prostate Cancer Nuclear Medicine Diagnostics Market?
An increasing incidence of prostate cancer is anticipated to fuel the expansion of the prostate cancer nuclear medicine diagnostics market moving ahead. Prostate cancer is a malignancy originating in the prostate, which is a small, walnut-sized male gland responsible for creating seminal fluid that feeds and carries sperm. This growing prevalence stems from factors such as an aging demographic, shifts in lifestyle, and hereditary predispositions. These diagnostics offer crucial data, empowering medical professionals to offer more accurate, impactful, and individualized treatment to those suffering from prostate cancer. To illustrate, in February 2024, the World Health Organization, a Switzerland-based specialized agency dedicated to global public health, forecasted that by 2050, new cancer cases would exceed 35 million, indicating a 77% rise from the estimated 20 million cases in 2022. Consequently, the increased occurrence of prostate cancer acts as a key driver for the prostate cancer nuclear medicine diagnostics market.
What Market Segments Are Evaluated Within The Prostate Cancer Nuclear Medicine Diagnostics Market?
The prostate cancer nuclear medicine diagnostics market covered in this report is segmented –
1) By Type: Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)
2) By Test Type: Preliminary Tests, Confirmatory Tests
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT, Hybrid SPECT Or CT Imaging
2) By Positron Emission Tomography (PET): PET Or CT Imaging, PET Or MRI Imaging
Which Upcoming Trends Are Expected To Influence The Prostate Cancer Nuclear Medicine Diagnostics Market?
Leading companies within the prostate cancer nuclear medicine market are concentrating on developing advanced solutions, such as targeted alpha-particle radiotherapy, to improve treatment precision and reduce off-target effects. This specific radiotherapy utilizes radioactive isotopes that emit alpha particles to precisely eliminate cancer cells while preserving healthy tissue, thereby offering a highly localized and effective therapeutic choice. As an illustration, in March 2025, Actinium Pharmaceuticals Inc., a US-based company focused on antibody radiation conjugates and other targeted radiotherapies, introduced ATNM-400, which incorporates actinium-225 (Ac-225) radiotherapy. This therapy targets a non-prostate-specific membrane antigen that is overexpressed in prostate cancer patients, offering an alternative for individuals who are resistant to PSMA-targeted therapies like Pluvicto. Key attributes of ATNM-400 include its use of the alpha-particle emitter Ac-225, which can diminish off-target effects compared to beta-particle therapies, and its ability to target a distinct cancer marker to broaden its therapeutic applicability. The launch is accompanied by preclinical data demonstrating biodistribution, imaging, and efficacy across various dose levels, with additional results anticipated from Pluvicto-resistant prostate cancer models. ATNM-400 is expected to propel precision radiotherapy forward and enhance treatment possibilities for patients with prostate cancer.
Who Are The Top Market Participants Influencing The Prostate Cancer Nuclear Medicine Diagnostics Market?
Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc, NCM USA LLC, ABX Advanced Biochemical Compounds GmbH, Theragnostics Ltd, SpectronRx Inc
Read the full prostate cancer nuclear medicine diagnostics market report here:
Which Region Is Projected To Dominate The Prostate Cancer Nuclear Medicine Diagnostics Market During The Forecast Period?
North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2025. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Prostate Cancer Nuclear Medicine Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15906&type=smp
Browse Through More Reports Similar to the Global Prostate Cancer Nuclear Medicine Diagnostics Market 2026, By The Business Research Company
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report
Cancer Diagnostics Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Prostate Specific Antigen Psa Test Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model